Belgravia Appoints Dr. Sam Hanna Chief Medical Officer of Cannabis Dermatology Division
18 April 2018 - 9:00PM
BELGRAVIA CAPITAL INTERNATIONAL INC. (CSE:BLGV) (OTCQB:BLGVF)
(“Belgravia” or the “Company”) has appointed Dr. Sam Hanna as Chief
Medical Officer of its cannabis dermatology division. Dr.
Hanna is a well-recognized Canadian dermatologist with experience
in numerous clinical studies for dermatology drugs across North
America.
Belgravia Dermatology Division – ICP
Organics:
The Company announced the appointment of Dr.
Hanna on January 10, 2018, as Special Advisor to Belgravia’s wholly
owned subsidiary, ICP Organics. Dr. Hanna now assumes leadership
for all medical aspects of development of cannabinoid based active
pharmaceutical ingredients for dermatological conditions. Dr.
Hanna, with the assistance of a biotechnology consultant, has
completed initial market studies. The Company has selected specific
dermatological indications for topical application of medically
claimed drugs. Dr. Hanna is currently engaged in careful analysis
of relevant scientific studies in order to establish developmental
approaches. This includes selecting biological markers and
drug delivery methodologies. He will also add to the technical team
and build out regulatory, and marketing staff and
consultants. Dr. Hanna has previously participated in
numerous dermatology clinical studies.
Dr. Sam Hanna, Chief Medical Officer of ICP
Organics stated: “There are currently dermatological conditions,
such as certain types of dermatitis and psoriasis where the medical
needs are not yet fully satisfied by current treatments.
There is good evidence that cannabinoids may provide
therapeutic value. I am excited to be working with ICP Organics in
the development of cannabinoid-related ethical drug products. For
example, Cannabidiol has been associated with reduced keratinocyte
proliferation and lipostatic effects. Related molecules have
relevant effects in dermatology impacting androgenicity and
inflammation. We are currently adding to the technical team and
working on establishing intellectual property strategies. In
addition, we are defining the scope of the necessary pre-clinical
work that will lead to Phase 1 clinical trials.”
Mr. Mehdi Azodi, President and Chief Executive
Officer of the Company stated: “We are pleased to welcome Dr. Hanna
as Chief Medical Officer. When Dr. Hanna joined the Company,
initially as special advisor, we made reference to the fact that
the Cannabinoid market is growing rapidly and that according to the
Journal of Clinical Investigation there is sufficient scientific
data to strongly encourage future study in clinical trials in skin
disease areas. In addition to carrying out ethical drug work
we are also defining faster-to-market products, which will be
marketable in Canada on an accelerated basis as the House of
Commons and the Senate approve the new cannabis legislation.
Such products may include claimed products that would likely be
regulated, in part, as Natural Health Products. Longer-term
ethical products are those that would be regulated under the Food
and Drugs Act in Canada and the Food and Drug Administration in the
United States. Both areas are of interest to us.”
Mr. Azodi continued: “We expect to make a series
of announcements over the next few weeks regarding Belgravia and
ICP Organics developments in this area. Dr. Hanna, with the
assistance of another medical advisor, Dr. Shoaib Sheikh, and other
biotechnology consultants are advancing our plans aggressively. We
are also engaging at present patent attorneys and laboratories
experienced in pre-clinical and clinical testing and the handling
of cannabis-derived ingredients.”
Dr. Hanna will be joining the Board of Directors
of ICP Organics. Ms. Genevieve Roch-Decter and Ms. Nicole
Marchand are stepping down from the Board but will continue as
consultants. Additional Board appointees can be expected in the
near term.
The Company is grateful to Ms. Roch-Decter and
Ms. Marchand for their contributions to the Company in its various
stages of development. They will continue to provide
financial advisory services to Belgravia Capital.
Belgravia Capital Business Model:
Belgravia continues to take a multi-tiered
approach in the development of its licit cannabis value added
portfolio of investments and operating businesses. Belgravia
Incubator identifies and finances early stage companies where
Belgravia believes it can add value. Belgravia Holdings makes
measured investments in public and private companies, primarily
Cannabis related, but also in technology verticals. Belgravia
Royalty and Management Services has developed a targeted royalty
and fee income model, with revenues currently in place.
Additional specific information about the diversified model will be
provided over the coming weeks.
About Belgravia
Belgravia Capital International Inc. is focused
on its three core business divisions: Incubation, Investments and
also Royalty and Management Services. Belgravia will also develop
new companies with a focus on the cannabis industry. The
Incubation division will provide services to support the
development of early-stage companies in the Cannabis space and
other technology areas. Belgravia Holdings, the
Investments division, invests in various private and public
companies with a focus on licit cannabis, technology, and, on an
opportunistic basis, resources. Belgravia and Royalty
and Management Services has developed a targeted royalty and fee
income model.
In the Cannabis space, the Company’s geographic
focus is primarily in Canada. Further, the developing cash
and investment asset base can also support international expansion
on a selective basis. Canada has powerful national government
legislation leadership in Cannabis, Cannabis friendly and
supportive physicians, and the world’s strongest Cannabis capital
markets.
For more information, please visit
www.belgraviacapital.ca
Forward-Looking
Statements Certain information set forth in this news
release may contain forward-looking statements that involve
substantial known and unknown risks and uncertainties and other
factors which may cause the actual results, performance or
achievements of the Company to be materially different from any
future results, performance or achievements expressed or implied by
such forward-looking statements. Forward-looking statements include
statements that use forward-looking terminology such as “may”,
“will”, “expect”, “anticipate”, “believe”, “continue”, “potential”
or the negative thereof or other variations thereof or comparable
terminology. Such forward-looking statements include, without
limitation, statements regarding planned investment activities
& related returns, trends in the markets for fertilizers and
medicinal or recreational use of cannabis, the timing or assurance
of the legalization of recreational cannabis, the timing for
completion of research and development activities, the potential
value of royalties from water and other resources, and other
statements that are not historical facts. These forward-looking
statements are subject to numerous risks and uncertainties, certain
of which are beyond the control of the Company, including, but not
limited to, changes in market trends, the completion, results and
timing of research undertaken by the Company, risks associated with
resource assets, the impact of general economic conditions,
commodity prices, industry conditions, dependence upon regulatory,
environmental, and governmental approvals, the uncertainty of
obtaining additional financing, and risks associated with cannabis
use for medicinal or recreational purposes. Readers are cautioned
that the assumptions used in the preparation of such information,
although considered reasonable at the time of preparation, may
prove to be imprecise and, as such, undue reliance should not be
placed on forward-looking statements.
For More Information, Please
Contact:Mehdi Azodi, President & CEOBelgravia Capital
International Inc.(416) 779-3268 mazodi@blgv.ca
Belgravia Hartford Capital (CSE:BLGV)
Historical Stock Chart
From Nov 2024 to Dec 2024
Belgravia Hartford Capital (CSE:BLGV)
Historical Stock Chart
From Dec 2023 to Dec 2024